Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

BACKGROUND/AIMS: Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Jap...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Chang, Chen-Wang, Wei, Shu-Chen, Chou, Jen-Wei, Hsu, Tzu-Chi, Chuang, Chiao-Hsiung, Lin, Ching-Pin, Hsu, Wen-Hung, Yen, Hsu-Heng, Lin, Jen-Kou, Fang, Yi-Jen, Wang, Horng-Yuan, Lin, Hung-Hsin, Wu, Deng Cheng, Ni, Yen Hsuan, Wang, Cheng-Yi, Wong, Jau-Min
格式: Artigo
語言:Inglês
出版: Korean Association for the Study of Intestinal Diseases 2014
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4214955/
https://ncbi.nlm.nih.gov/pubmed/25374494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2014.12.4.287
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍